Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
NCT05388149
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
15
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
HER2-positive Breast Cancer
Interventions
DRUG:
Neratinib
Sponsor
University Health Network, Toronto